Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study

Conclusion: This enhanced pharmacodynamic (PD) response enabled identification of early responders with a superior TCZ clinical benefit. This biomarker model may assist in the identification of TCZ responsive RA patients and thus potentially benefit individual patients.Trial registrationClinicaltrials.gov: NCT00106535. JAN 2005
Source: Epidemiologic Perspectives and Innovations - Category: Epidemiology Authors: Source Type: research